Researchers at the University of Georgia (UGA), David Chu and Uma Singh, have made a new discovery with the development of a new molecule, potentially revolutionizing the treatment for the varicella zoster virus, which is responsible for both chickenpox and shingles.
This development could also extend to treating the viruses that cause oral and genital herpes, offering hope to millions affected worldwide.
The varicella zoster virus, after causing chickenpox, remains dormant in the body. It can reactivate later in life, leading to shingles, a painful condition that affects many, especially the elderly.
Furthermore, herpes simplex virus 1 and 2 cause oral and genital herpes, respectively, conditions that are not only painful but also carry a significant social stigma and psychological impact.
The Novel Molecule: POM-L-BHDU
The molecule, named POM-L-BHDU, stands out for its safety profile, making it suitable even for cancer patients who may have compromised immune systems.
It’s adaptable for oral, intravenous, or topical application, indicating a broad potential use, including creams for managing herpes outbreaks and treating shingles.
What sets POM-L-BHDU apart is its higher potency against these viruses compared to existing treatments. Many of the current drugs have lost their effectiveness over time due to increasing drug resistance among these viruses. Moreover, existing treatments often come with severe side effects or offer limited efficacy.
The Advantages of Topical Application
One of the most promising aspects of POM-L-BHDU is its effectiveness when applied directly to the skin. This method not only prevents the virus from spreading to other parts of the body but also reduces the overall amount of the drug entering the bloodstream.
This localized approach minimizes potential side effects, making the treatment safer for a broader range of patients.
The molecule’s capability to act against both the varicella zoster virus and the herpes simplex viruses showcases its wide-reaching potential.
With successful in vitro and in vivo tests in mouse models, and promising results from topical applications on human skin, POM-L-BHDU is on its way to revolutionizing how these viruses are treated.
Looking Forward
The vision for POM-L-BHDU extends to making its topical formula available over the counter. This accessibility could dramatically change how patients manage their conditions, allowing for immediate, convenient treatment at the first sign of an outbreak.
Having licensed the molecule to Anterogen Co., the UGA Research Foundation is now looking towards phase 1 clinical trials, marking a significant step forward in bringing this innovative treatment to patients.
This development not only offers new hope for those affected by herpes and shingles but also exemplifies the impact of dedicated research in addressing longstanding medical challenges.
The study, published in the Journal of Medicinal Chemistry, underscores the potential of POM-L-BHDU to change the landscape of viral infection treatment significantly.
If you care about wellness, please read studies about how ultra-processed foods and red meat influence your longevity, and why seafood may boost healthy aging.
For more information about wellness, please see recent studies that olive oil may help you live longer, and vitamin D could help lower the risk of autoimmune diseases.
Copyright © 2024 Knowridge Science Report. All rights reserved.
